Sermorelin

Sermorelin Acetate (GHRH 1-29)

Evidence & Status

  • FDA Approved
  • Moderate Evidence
  • Moderate

At a Glance

A synthetic version of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the natural signal the hypothalamus uses to prompt pituitary growth hormone production. Studied in the context of age-related decline in growth hormone secretion and pituitary function assessment.

Plain English

Researchers study Sermorelin because it mimics the natural signal the hypothalamus sends to the pituitary gland to trigger growth hormone release. Scientists are interested in whether stimulating this natural pathway — rather than introducing exogenous growth hormone directly — represents a physiologically different approach to studying age-related changes in the growth hormone axis. It is one of the older and better-studied growth hormone secretagogues, with human clinical data supporting its effects on pituitary responsiveness.

Overview

A synthetic analogue of the first 29 amino acids of endogenous GHRH. Geref was historically FDA-approved, but the product was discontinued; this history must not be represented as a current FDA-approved product or as support for anti-aging use.

Research Summary

Sermorelin (GHRH(1–29)-NH₂) has documented human pharmacodynamic activity: intravenous administration produces dose-dependent growth-hormone release in normal men, with a reported IV disappearance half-time of approximately 4.3 minutes (Barron et al. 1985; Soule et al. 1994). Prolonged subcutaneous infusion promoted growth in children with partial GH insufficiency over one year (Brain et al. 1990). As Geref, sermorelin was historically FDA-approved; the marketed product was voluntarily withdrawn, and FDA determined the withdrawal was not for reasons of safety or effectiveness. This historical regulatory status and documented human pharmacodynamic data do not establish clinical benefit for adult anti-aging, longevity, sleep, or body-composition claims in contemporary compounded formulations.

Research Areas

  • GH deficiency
  • Pituitary function
  • Anti-aging
  • Sleep quality
  • Body composition

Safety & Risks

Serious Risks

  • Long-term safety and outcome data for contemporary compounded use have not been established

Reported Side Effects

  • Injection site redness/pain
  • Flushing
  • Headache
  • Dizziness
  • Nausea
United States
Historically FDA-approved as Geref; the branded product was discontinued and no current FDA-approved sermorelin product is marketed
United Kingdom
No authorized sermorelin medicinal product identified in this review
Australia
No authorized sermorelin medicinal product identified in this review
Canada
No authorized sermorelin medicinal product identified in this review

Citations & Sources